| Literature DB >> 26396516 |
Christian Veauthier1, Gunnar Gaede2, Helena Radbruch3, Joern-Peter Sieb4, Klaus-Dieter Wernecke5, Friedemann Paul6.
Abstract
BACKGROUND: There are few studies describing periodic limb movement syndrome (PLMS) in rapid eye movement (REM) sleep in patients with narcolepsy, restless legs syndrome, REM sleep behavior disorder, and spinal cord injury, and to a lesser extent, in insomnia patients and healthy controls, but no published cases in multiple sclerosis (MS). The aim of this study was to investigate PLMS in REM sleep in MS and to analyze whether it is associated with age, sex, disability, and laboratory findings.Entities:
Keywords: clinical neurophysiology; disability; polysomnography; restless legs syndrome; sleep disorders; spinal cord
Year: 2015 PMID: 26396516 PMCID: PMC4574879 DOI: 10.2147/NDT.S83350
Source DB: PubMed Journal: Neuropsychiatr Dis Treat ISSN: 1176-6328 Impact factor: 2.570
Differences between the two subgroups: demographic and polysomnographic parameters
| All patients | Group 1 | Group 2 | |||
|---|---|---|---|---|---|
| Number of patients | n (%) | 66 (100) | 59 (89.4) | 7 (10.6) | |
| Sex (male/female) | n (%) | 21 (31.8)/45 (68.2) | 4 (6.1)/3 (4.5) | 18 (27.3)/41 (62.1) | 0.162 |
| Age (years) | Mean ± SD | 43.6±10.0 | 43.3±10.2 | 46.4±6.6 | 0.431 |
| Min–max | 20–66 | 20–66 | 38–57 | ||
| Range 25%–75% | 38.75–49.0 | 38.5–49.0 | 41.5–51.0 | ||
| EDSS | Mean ± SD | 2.7±1.8 | 2.4±1.5 | 4.9±1.5 | |
| Range 25%–75% | 1.5–3.6 | 1.6–3.0 | 2.5–7.0 | ||
| Disease-modifying therapy | n (%) | 50 (75.8) | 44 (66.7) | 6 (9.1) | |
| Glatiramer acetate | n (%) | 24 (36.4) | 20 (30.3) | 4 (6.1) | |
| Interferon | n (%) | 22 (33.3) | 21 (31.8) | 1 (1.5) | |
| Immunoglobulins | n (%) | 1 (1.5) | 0 (0.0) | 1 (1.5) | |
| Mitoxantrone | n (%) | 2 (3.0) | 2 (3.0) | 0 (0.0) | |
| Natalizumab | n (%) | 1 (1.5) | 1 (1.5) | 0 (0.0) | |
| Cortisone | n (%) | 2 (3.0) | 2 (3.0) | 0 (0.0) | |
| No therapy | n (%) | 14 (21.2) | 13 (19.7) | 1 (1.5) | |
| Disease course | |||||
| RRMS | n (%) | 46 (69.7) | 42 (63.6) | 4 (6.1) | |
| SPMS | n (%) | 16 (24.2) | 13 (19.7) | 3 (4.5) | |
| PPMS | n (%) | 4 (6.1) | 4 (6.1) | 0 (0.0) | |
| PLMI (per hour of sleep) | Mean ± SD | 23.1±29.8 | 18.3±22.8 | 63.5±49.4 | |
| Range 25%–75% | 2.3–36.0 | 2.0–28.4 | 11.5–121.3 | ||
| REM-PLMI (per hour of REM sleep) | Mean ± SD | 6.0±18.5 | 1.5±2.6 | 44.5±41.2 | < |
| Range 25%–75% | 0.0–3.7 | 0.0–1.8 | 13.8–69.0 | ||
| PLM arousal index (per hour of sleep) | Mean ± SD | 2.7±4.2 | 2.3±3.9 | 6.6±5.1 | |
| Range 25%–75% | 0.2–3.6 | 0.2–1.9 | 0.8–12.7 | ||
| Sleep efficiency (% TST/TiB) | Mean ± SD | 74.8±14.9 | 74.0±15.5 | 82.3±4.7 | 0.151 |
| Range 25%–75% | 67.1–85.3 | 64.2–85.1 | 77.6–85.7 | ||
| NREM 1+2 (%/TiB) | Mean ± SD | 51.2±12.2 | 50.9±12.6 | 54.2±7.1 | 0.539 |
| Range 25%–75% | 43.6–62.5 | 41.6–62.5 | 48.2–62.6 | ||
| NREM 3+4 (%/TiB) | Mean ± SD | 13.9±12.0 | 14.0±6.6 | 13.4±9.7 | 0.958 |
| Range 25%–75% | 6.6–18.8 | 12.3–18.5 | 4.1–23.8 | ||
| REM (%/TiB) | Mean ± SD | 14.3±7.4 | 14.0±7.6 | 16.2±5.8 | 0.338 |
| Range 25%–75% | 10.6–17.5 | 10.5–17.0 | 11.8–21.7 | ||
| Sleep latency (minutes) | Mean ± SD | 31.9±35.7 | 33.4±11.0 | 19.3±13.0 | 0.307 |
| Range 25%–75% | 12.5–41.0 | 37.4–42.0 | 9.6–42.0 | ||
| Number of awakenings | Mean ± SD | 26.7±12.4 | 26.9±18.0 | 24.4±17.0 | 0.827 |
| Range 25%–75% | 18.0–32.0 | 12.7–32.0 | 10.2–34.0 | ||
| Wake after sleep onset (minutes) | Mean ± SD | 83.8±57.3 | 86.4±43.0 | 61.9±36.0 | 0.539 |
| Range 25%–75% | 43.0–120.0 | 59.7–128.0 | 22.2–80.0 |
Notes:
Due to the small sample size in the different subgroups and because of different disease-modifying therapies and different disease courses, a statistical analysis of the difference between different disease courses and different disease-modifying therapies was not possible.
One patient with intrathecal application of triamcinolone acetonide and one patient with repetitive use of pulse therapy with methylprednisolone. Group 1, patients with REM-PLMI <10 per hour; Group 2, patients with REM-PLMI ≥10 per hour. P-values given in bold demonstrate a significant difference between the two subgroups.
Abbreviations: SD, standard deviation; min, minimum; max, maximum; EDSS, expanded disability status scale; RRMS, relapsing–remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; PPMS, primary progressive multiple sclerosis; PLMI, periodic limb movement index; REM-PLMI, PLMI during REM sleep; REM, rapid eye movement; TST, total sleep time; TiB, time spent in bed; NREM, nonrapid eye movement.
Figure 1Typical examples of PLM during REM sleep.
Notes: (A) Example of PLMs during REM sleep in a 30-second polysomnographic epoch. (B) The same polysomnography with ten 30-second epochs showing PLM during REM.
Abbreviations: PLM, periodic limb movement; REM, rapid eye movement; EEG, electroencephalography; EMG, electromyogram; EOG, electrooculogram.